| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
145,981,000 |
| Market
Cap: |
1.20(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.97 - $8.3 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 6.8 |
| Insider 6 Months : 9 |
| Insider 3/6 Months : 16.1 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
12,000 |
81,610 |
85,610 |
85,610 |
| Total Buy Value |
$95,852 |
$170,899 |
$178,179 |
$178,179 |
| Total People Bought |
1 |
3 |
4 |
4 |
| Total Buy Transactions |
1 |
3 |
4 |
4 |
| Total Shares Sold |
0 |
245,938 |
245,938 |
271,454 |
| Total Sell Value |
$0 |
$310,668 |
$310,668 |
$341,047 |
| Total People Sold |
0 |
4 |
4 |
4 |
| Total Sell Transactions |
0 |
7 |
7 |
10 |
| End Date |
2025-03-16 |
2024-12-13 |
2024-06-14 |
2023-06-15 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Klassen Preston |
President & Head of R & D |
• • – |
2025-06-03 |
4 |
B |
$7.99 |
$95,852 |
D/D |
12,000 |
48,055 |
0.01 |
2% |
|
| Baltimore David |
|
– • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
I/I |
62,500 |
62,500 |
|
- |
|
| Baltimore David |
|
– • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
84,669 |
|
- |
|
| Rosen Hugh |
|
– • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
64,271 |
|
- |
|
| Collier Kathryn J |
|
– • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
69,240 |
|
- |
|
| Witz Pascale |
|
– • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
67,233 |
|
- |
|
| Papadopoulos Stelios |
|
– • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
1,040,888 |
|
- |
|
| Rastetter William H |
|
– • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
I/I |
62,500 |
101,556 |
|
- |
|
| Huang Alice Shih-Hou |
|
– • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
I/I |
62,500 |
84,669 |
|
- |
|
| Huang Alice Shih-Hou |
|
– • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
62,500 |
|
- |
|
| Nunn Jason Raleigh |
|
– • – |
2025-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
62,500 |
|
- |
|
| Hagan Joseph P |
Chief Executive Officer |
• • – |
2025-01-30 |
4 |
B |
$1.09 |
$54,260 |
D/D |
50,000 |
260,808 |
0.01 |
730% |
|
| Baltimore David |
|
– • – |
2025-01-30 |
4 |
B |
$1.06 |
$20,787 |
D/D |
19,610 |
22,169 |
0.01 |
730% |
|
| Calsada Crispina |
Chief Financial Officer |
• – – |
2025-01-14 |
4 |
AS |
$1.26 |
$6,427 |
D/D |
(5,088) |
45,478 |
|
544% |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2025-01-14 |
4 |
AS |
$1.26 |
$6,427 |
D/D |
(5,088) |
49,546 |
|
544% |
|
| Hagan Joseph P |
Chief Executive Officer |
• • – |
2025-01-14 |
4 |
AS |
$1.26 |
$14,860 |
D/D |
(11,764) |
210,808 |
|
544% |
|
| Calsada Crispina |
Chief Financial Officer |
• – – |
2025-01-13 |
4 |
AS |
$1.26 |
$48,906 |
D/D |
(38,716) |
50,566 |
|
508% |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2025-01-13 |
4 |
AS |
$1.26 |
$48,693 |
D/D |
(38,547) |
54,634 |
|
508% |
|
| Klassen Preston |
President & Head of R & D |
• • – |
2025-01-13 |
4 |
AS |
$1.26 |
$39,721 |
D/D |
(31,445) |
36,055 |
|
508% |
|
| Hagan Joseph P |
Chief Executive Officer |
• • – |
2025-01-13 |
4 |
AS |
$1.26 |
$145,634 |
D/D |
(115,290) |
222,572 |
|
508% |
|
| Calsada Crispina |
Chief Financial Officer |
• – – |
2025-01-09 |
4 |
A |
$1.30 |
$112,300 |
D/D |
83,500 |
89,282 |
|
- |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2025-01-09 |
4 |
A |
$1.30 |
$113,360 |
D/D |
84,125 |
93,181 |
|
- |
|
| Klassen Preston |
President & Head of R & D |
• • – |
2025-01-09 |
4 |
A |
$1.30 |
$90,000 |
D/D |
67,500 |
67,500 |
|
- |
|
| Hagan Joseph P |
Chief Executive Officer |
• • – |
2025-01-09 |
4 |
A |
$1.30 |
$378,100 |
D/D |
280,750 |
337,862 |
|
- |
|
| Collier Kathryn J |
|
– • – |
2024-07-25 |
4 |
B |
$1.82 |
$7,280 |
D/D |
4,000 |
6,740 |
0.01 |
-7% |
|
161 Records found
|
|
Page 1 of 7 |
|
|
0.11 (1.36%) 
